Cargando…
Clinical trial links oncolytic immunoactivation to survival in glioblastoma
Immunotherapy failures can result from the highly suppressive tumour microenvironment that characterizes aggressive forms of cancer such as recurrent glioblastoma (rGBM)(1,2). Here we report the results of a first-in-human phase I trial in 41 patients with rGBM who were injected with CAN-3110—an onc...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620094/ https://www.ncbi.nlm.nih.gov/pubmed/37853118 http://dx.doi.org/10.1038/s41586-023-06623-2 |